TypeName: Business Offer
Offer Date:2018/09/29
Country: United States
Summary: Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).
https://www.bocsci.com/olmutinib-cas-1353550-13-6-item-470842.html
Description: [RequestDescription]
OfferId: 2163
Name:Alex Brown
Telphone: